Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 6 (2009), Issue 4 (April)

  1. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
    J Natl Cancer Inst, 101(7): 519-32. [Abstract] [Full-text]
  2. Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).
    Br J Cancer, 100(7): 1068-72. [Abstract] [Full-text]
  3. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.
    Br J Cancer, 100(7): 1198-204. [Abstract] [Full-text]
  4. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer.
    Br J Cancer, 100(7): 1165-74. [Abstract] [Full-text]
  5. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.
    Int J Cancer, 124(11): 2683-9. [Abstract] [Full-text]
  6. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
    Exp Mol Pathol, 86(2): 108-13. [Abstract] [Full-text]
  7. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
    BJU Int, 103(8): 1058-63. [Abstract] [Full-text]
  8. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    BJU Int, 103(8): 1064-8. [Abstract] [Full-text]
  9. Evaluating and grading cystographic leakage: correlation with clinical outcomes in patients undergoing robotic prostatectomy.
    BJU Int, 103(8): 1108-10. [Abstract] [Full-text]
  10. Regulation of prostate cancer progression by galectin-3.
    Am J Pathol, 174(4): 1515-23. [Abstract] [Full-text]
  11. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
    Lancet Oncol, 10(4): 370-80. [Abstract] [Full-text]
  12. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
    Am J Pathol, 174(4): 1492-503. [Abstract] [Full-text]
  13. Nitric oxide synthase gene polymorphisms and prostate cancer risk.
    Carcinogenesis, 30(4): 621-5. [Abstract] [Full-text]
  14. Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia.
    Eur J Surg Oncol, 35(5): 527-31. [Abstract] [Full-text]
  15. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors.
    Cancer Cell, 15(4): 283-93. [Abstract] [Full-text]
  16. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.
    Cancer Cell, 15(4): 270-82. [Abstract] [Full-text]
  17. Unraveling the complexities of androgen receptor signaling in prostate cancer cells.
    Cancer Cell, 15(4): 245-7. [Abstract] [Full-text]
  18. Hypothermic nerve-sparing radical prostatectomy: rationale, feasibility, and effect on early continence.
    Urology, 73(4): 691-6. [Abstract] [Full-text]
  19. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Clin Immunol, 131(1): 1-10. [Abstract] [Full-text]
  20. Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy.
    Urology, 73(4): 881-6. [Abstract] [Full-text]
  21. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Urology, 73(4): 860-5; discussion 865-7. [Abstract] [Full-text]
  22. Effect of aberrant vasculature during cryosurgery for prostate cancer.
    Urology, 73(4): 754-5. [Abstract] [Full-text]
  23. Chronic periglandular inflammation on prostate needle biopsy does not increase the likelihood of cancer on subsequent biopsy.
    Urology, 73(4): 845-9. [Abstract] [Full-text]
  24. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.
    Urology, 73(4): 850-5. [Abstract] [Full-text]
  25. Radical prostatectomy after previous prostate surgery: effects on surgical difficulty and pathologic outcomes.
    Urology, 73(4): 856-9. [Abstract] [Full-text]
  26. D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells.
    Biochem Biophys Res Commun, 382(1): 96-101. [Abstract] [Full-text]
  27. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}.
    J Biol Chem, 284(15): 10004-12. [Abstract] [Full-text]
  28. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
    Cancer Lett, 278(1): 82-7. [Abstract] [Full-text]
  29. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
    Cancer Invest, 27(4): 369-75. [Abstract] [Full-text]
  30. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.
    Oncogene, 28(14): 1714-24. [Abstract] [Full-text]
  31. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study.
    Cancer Invest, 27(4): 430-4. [Abstract] [Full-text]
  32. Ejaculatory function after permanent 125I prostate brachytherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(1): 126-32. [Abstract] [Full-text]
  33. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
    J Urol, 181(5): 2320-5. [Abstract] [Full-text]
  34. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
    Int J Radiat Oncol Biol Phys, 74(1): 104-9. [Abstract] [Full-text]
  35. Metabolic complications of androgen deprivation therapy for prostate cancer.
    J Urol, 181(5): 1998-2006; discussion 2007-8. [Abstract] [Full-text]
  36. Prostate cancer screening and treatment in the transplant population: current status and recommendations.
    J Urol, 181(5): 2018-25; discussion 2025-6. [Abstract] [Full-text]
  37. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
    J Urol, 181(5): 2064-70. [Abstract] [Full-text]
  38. Hospice and emergency room use by disadvantaged men dying of prostate cancer.
    J Urol, 181(5): 2084-9. [Abstract] [Full-text]
  39. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.
    J Urol, 181(5): 2071-5; discussion 2076. [Abstract] [Full-text]
  40. Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates.
    J Urol, 181(5): 2077-82; discussion 2082-3. [Abstract] [Full-text]
  41. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
    Int J Radiat Oncol Biol Phys, 74(1): 115-25. [Abstract] [Full-text]
  42. Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging.
    Int J Radiat Oncol Biol Phys, 74(1): 110-4. [Abstract] [Full-text]
  43. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids.
    Biomaterials, 30(16): 3020-7. [Abstract] [Full-text]
  44. Immunohistochemical evaluation of prostate needle biopsies using saved interval sections vs new recut sections from the block: a prospective comparison.
    Am J Clin Pathol, 131(5): 683-7. [Abstract] [Full-text]
  45. Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry.
    Oncogene, 28(15): 1792-806. [Abstract] [Full-text]
  46. Reproducibility of plasma alkylresorcinols during a 6-week rye intervention study in men with prostate cancer.
    J Nutr, 139(5): 975-80. [Abstract] [Full-text]
  47. Lack of comprehension of common prostate cancer terms in an underserved population.
    J Clin Oncol, 27(12): 2015-21. [Abstract] [Full-text]
  48. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    J Clin Oncol, 27(12): 2022-9. [Abstract] [Full-text]
  49. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
    Urology, 73(5): S4-10. [Abstract] [Full-text]
  50. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Urology, 73(5): S36-43. [Abstract] [Full-text]
  51. Current prostate cancer treatments: effect on quality of life.
    Urology, 73(5): S28-35. [Abstract] [Full-text]
  52. Risk of developing prostate cancer in the future: overview of prognostic biomarkers.
    Urology, 73(5): S21-7. [Abstract] [Full-text]
  53. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
    Urology, 73(5): S11-20. [Abstract] [Full-text]
  54. Central quadrant procurement of radical prostatectomy specimens.
    Prostate, 69(7): 770-3. [Abstract] [Full-text]
  55. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
    Prostate, 69(7): 787-98. [Abstract] [Full-text]
  56. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
    Prostate, 69(7): 774-86. [Abstract] [Full-text]
  57. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
    Prostate, 69(7): 761-9. [Abstract] [Full-text]
  58. Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation.
    Prostate, 69(7): 719-26. [Abstract] [Full-text]
  59. Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines.
    Prostate, 69(7): 706-18. [Abstract] [Full-text]
  60. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Prostate, 69(7): 755-60. [Abstract] [Full-text]
  61. Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.
    Prostate, 69(7): 727-36. [Abstract] [Full-text]
  62. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Prostate, 69(7): 744-54. [Abstract] [Full-text]
  63. Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense.
    Prostate, 69(7): 689-98. [Abstract] [Full-text]
  64. Human prostasomes contain chromosomal DNA.
    Prostate, 69(7): 737-43. [Abstract] [Full-text]
  65. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Int J Cancer, 124(12): 2989-96. [Abstract] [Full-text]
  66. The relation of alpha-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis.
    Am J Clin Nutr, 89(5): 1558S-1564S. [Abstract] [Full-text]
  67. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.
    Oncogene, 28(16): 1853-63. [Abstract] [Full-text]
  68. A pain in the neck -- an unexpected complication of transrectal ultrasound and biopsy.
    Br J Radiol, 82(977): e92-4. [Abstract] [Full-text]
  69. Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor.
    Cancer Lett, 278(2): 220-9. [Abstract] [Full-text]
  70. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Am J Pathol, 174(5): 1869-79. [Abstract] [Full-text]
  71. Global levels of histone modifications predict prognosis in different cancers.
    Am J Pathol, 174(5): 1619-28. [Abstract] [Full-text]
  72. Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.
    Am J Pathol, 174(5): 1921-30. [Abstract] [Full-text]
  73. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
    Adv Anat Pathol, 16(3): 145-53. [Abstract] [Full-text]
  74. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
    Urology, 73(5): 1104-9. [Abstract] [Full-text]
  75. Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy.
    Urology, 73(5): 1056-60. [Abstract] [Full-text]
  76. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Urology, 73(5): 935-9. [Abstract] [Full-text]
  77. Are total prostate-specific antigen serum levels in cirrhotic men different from those in normal men?
    Urology, 73(5): 1032-5. [Abstract] [Full-text]
  78. Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.
    Urology, 73(5): 1098-103. [Abstract] [Full-text]
  79. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Urology, 73(5): 1087-91. [Abstract] [Full-text]
  80. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
    Urology, 73(5): 1092-7. [Abstract] [Full-text]
  81. Magnetic resonance imaging is a complementary method to stereological measurement of testicular volume.
    Urology, 73(5): 1131-5. [Abstract] [Full-text]
  82. PrLZ expression is associated with the progression of prostate cancer LNCaP cells.
    Mol Carcinog, 48(5): 432-40. [Abstract] [Full-text]
  83. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.
    Prostate, 69(8): 874-85. [Abstract] [Full-text]
  84. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells.
    Prostate, 69(8): 861-73. [Abstract] [Full-text]
  85. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Prostate, 69(8): 895-907. [Abstract] [Full-text]
  86. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
    Prostate, 69(8): 886-94. [Abstract] [Full-text]
  87. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls.
    Eur J Cancer, 45(8): 1443-9. [Abstract] [Full-text]
  88. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.
    Prostate, 69(8): 827-37. [Abstract] [Full-text]
  89. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
    Prostate, 69(8): 799-809. [Abstract] [Full-text]
  90. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
    Prostate, 69(8): 810-9. [Abstract] [Full-text]
  91. Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer.
    Prostate, 69(8): 820-6. [Abstract] [Full-text]
  92. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.
    Prostate, 69(8): 851-60. [Abstract] [Full-text]
  93. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband.
    Br J Cancer, 100(9): 1508-12. [Abstract] [Full-text]
  94. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging.
    Radiology, 251(2): 408-14. [Abstract] [Full-text]
  95. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
    J Clin Oncol, 27(13): 2137-43. [Abstract] [Full-text]
  96. Phase II study of sunitinib in men with advanced prostate cancer.
    Ann Oncol, 20(5): 913-20. [Abstract] [Full-text]
  97. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy.
    BJU Int, 103(9): 1168-72. [Abstract] [Full-text]
  98. Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells.
    BJU Int, 103(9): 1275-83. [Abstract] [Full-text]
  99. Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas.
    BJU Int, 103(9): 1184-9. [Abstract] [Full-text]
  100. The impact of training on service provision in laparoscopic radical prostatectomy.
    BJU Int, 103(9): 1231-4; discussion 1234-5. [Abstract] [Full-text]
  101. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    BJU Int, 103(9): 1179-83. [Abstract] [Full-text]
  102. Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens.
    BJU Int, 103(9): 1190-4. [Abstract] [Full-text]
  103. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
    BJU Int, 103(9): 1256-69. [Abstract] [Full-text]
  104. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    BJU Int, 103(9): 1173-8; discussion 1178. [Abstract] [Full-text]
  105. Periprostatic nerve block (PNB) alone vs PNB combined with an anaesthetic-myorelaxant agent cream for prostate biopsy: a prospective, randomized double-arm study.
    BJU Int, 103(9): 1195-8. [Abstract] [Full-text]
  106. The first 1000 cases of laparoscopic radical prostatectomy in the UK: evidence of multiple 'learning curves'.
    BJU Int, 103(9): 1224-30. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

The Prostate Cancer Treatment Book

The Prostate Cancer Treatment Book